Ernamín at the 55th Congress of the Spanish Society of Nephrology

Ernamín at the 55th Congress of the Spanish Society of Nephrology
From October 16–18, the 55th edition of the Congress of the Spanish Society of Nephrology (SEN) took place in Oviedo. For the first time, and following the launch of Ernamín, ERN Laboratories participated as a collaborator in the event, with a stand in the commercial exhibition area and by organizing a technical forum featuring high-level speakers.
The forum, titled “Use of Ketoanalogues for the Management of CKD in Spain: A New Reality”, brought together over one hundred nephrology professionals. Dr. Juan-Jesús Carrero, researcher at the Karolinska Institute in Sweden, and Dr. Pablo Molina, Head of the Nephrology Department at Hospital La Fe (València), presented evidence on low-protein diets in advanced CKD, the use of amino acid ketoanalogues in these patients, and the results of the ADHERENCE study. The forum was moderated by Dr. Huarte, Head of the Nephrology Department at Hospital San Millán-San Pedro de Logroño (La Rioja).

The ADHERENCE study is the first randomized clinical trial conducted with ketoanalogues in Spain, and its results, which reinforce existing evidence on the benefits of ketoanalogues, will be published soon in the journal Nefrología.
Ernamín is the only product available on the Spanish market (since last June) that contains a combination of essential amino acids and ketoanalogues, making it a unique nutritional tool for the dietary management of advanced CKD. Together with a very low-protein diet, Ernamín helps preserve kidney function, improves nutritional status, and delays the need for dialysis.
noticias relacionadas
Ernamín at the 55th Congress of the Spanish Society of Nephrology
From October 16–18, the 55th edition of the Congress of the Spanish Society of Nephrology (SEN) took place in Oviedo. For the first time, and following the launch of Ernamín, ERN Laboratories participated as a collaborator in the event, with a stand in the commercial exhibition area and by organizing a technical forum featuring high-level […]
Incremental Drug Innovation: A Priority Focus for Laboratorios ERN
David Solanes López, General Manager of Laboratorios ERN, was appointed Academician of the Royal Academy of Pharmacy of Catalonia on October 6, 2025, in the industrial section. Solanes dedicated his induction speech to incremental innovation, an area closely linked to his professional career and to Laboratorios ERN’s commitment to developing solutions that improve patients’ lives. […]
FDA has approved intravenous fosfomycin for the treatment of cUTI
On October 22, 2025, the U.S. Food and Drug Administration (FDA) approved intravenous fosfomycin for the treatment of complicated urinary tract infections (cUTI). Laboratorios ERN expresses its satisfaction with the recent approval by the U.S. Food and Drug Administration (FDA) of intravenous fosfomycin for the treatment of patients aged 18 years and older with complicated […]
Laboratorios ERN collaborates with the Master’s in Logistics and Supply Chain Management at the University of Barcelona
The collaboration with the Institut de Formació Contínua–IL3 allows students to apply their knowledge to a real case in the pharmaceutical sector. Laboratorios ERN has strengthened its ties with the academic field through a collaboration with the Master’s in Logistics and Supply Chain Management at the Institut de Formació Contínua–IL3, part of the University of […]
“Una rosa per no oblidar”
Once again, on the occasion of Sant Jordi’s Day, April 23rd, 2025, Laboratorios ERN has renewed its commitment to solidarity by joining the Fundació Alzheimer Catalunya. As we did in 2024, we wanted to convey a message of support to all people affected by Alzheimer’s disease. Each rose delivered represents much more than a flower: […]